Response Rates Following Total Neoadjuvant Therapy for Rectal Cancer

Pathologic Complete Response Rates

Total neoadjuvant therapy achieves pathologic complete response rates of approximately 22-26% when surgical specimens are examined, with clinical complete response or near-complete response rates reaching 71-76% depending on the chemotherapy sequencing strategy 1, 2
The American Society of Clinical Oncology guidelines demonstrate that total neoadjuvant therapy significantly improves pathologic complete response rates compared to standard neoadjuvant chemoradiation alone, with rates of 21.8-22.7% in randomized controlled trials 1, 2
Total neoadjuvant therapy provides a 74% relative improvement in pathologic complete response rates compared to chemoradiation, with a relative risk of 1.74 and a 95% confidence interval of 1.45-2.10 3

The American Society of Clinical Oncology reports clinical complete response rates of 11.1% with total neoadjuvant therapy versus 4.4% with chemoradiation alone, based on the STELLAR trial 1, 2
Clinical complete response rates are substantially lower than combined response metrics and show important discordance with pathologic findings, highlighting the difficulty of detecting complete response preoperatively 1, 2, 4

Approximately 50-60% of patients experience tumor downstaging following neoadjuvant therapy, according to the National Comprehensive Cancer Network 5
Total neoadjuvant therapy produces substantial tumor downstaging, with approximately 18-26% of patients achieving pathologic complete response when examining surgical specimens after neoadjuvant chemoradiation 2, 4

For patients pursuing nonoperative management after achieving clinical complete response, total mesorectal excision-free survival at 3 years was 41-53% depending on chemotherapy sequencing, as reported by the American Society of Clinical Oncology 1, 2
The 2-year local regrowth rate is 15.7% with nonoperative management protocols, with a 95% confidence interval of 11.6-20.1 2, 4
Approximately 95.4% of patients with regrowth successfully receive salvage therapy, with a 95% confidence interval of 89.6-99.3 2, 4

Magnetic resonance imaging and endoscopy cannot reliably distinguish complete responders preoperatively, with magnetic resonance imaging showing only 64% overall accuracy for response assessment 6
The definition of complete response matters, with pathologic complete response plus sustained clinical complete response yielding much higher rates than pathologic complete response alone 1, 2
Response rates vary significantly by total neoadjuvant therapy regimen, with consolidation chemotherapy showing slightly higher combined response rates than induction chemotherapy 1, 2, 8